Ryvu Therapeutics is selling at 19.80 as of the 14th of March 2025; that is 4.87% up since the beginning of the trading day. The stock's lowest day price was 19.0. Ryvu Therapeutics has hardly any chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 14th of December 2024 and ending today, the 14th of March 2025. Click here to learn more.
Although Ryvu Therapeutics' alpha and beta are two of the key measurements used to evaluate Ryvu Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ryvu Therapeutics stock to make a market-neutral strategy. Peer analysis of Ryvu Therapeutics could also be used in its relative valuation, which is a method of valuing Ryvu Therapeutics by comparing valuation metrics with similar companies.
When running Ryvu Therapeutics' price analysis, check to measure Ryvu Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ryvu Therapeutics is operating at the current time. Most of Ryvu Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ryvu Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ryvu Therapeutics' price. Additionally, you may evaluate how the addition of Ryvu Therapeutics to your portfolios can decrease your overall portfolio volatility.